The objective of this study was to evaluate the effect of a probiotic combination on the severity of oral mucositis (OM), which is a common, unpreventable complication induced by radiochemotherapy in patients with nasopharyngeal carcinoma who undergo concurrent radiochemotherapy (CCRT). METHODS: Eligible patients (n = 99) with locally advanced nasopharyngeal carcinoma who were undergoing CCRT were randomly assigned (2:1) to receive a probiotic combination or placebo during radiochemotherapy, and the incidence of severe OM (grade 3 or higher) was the primary endpoint. RESULTS: Patients taking the probiotic combination showed a significant reduction in the severity of OM. The incidences of grade 0, 1, 2, and 3 OM in the placebo group and the probiotic combination group were 0% and 12.07%, 0% and 55.17%, 54.29% and 17.24%, and 45.71% and 15.52%, respectively. Furthermore, CCRT greatly lowered the number of immune cells, whereas the probiotic combination markedly lowered the reduction rates of CD4 + T cells (76.59% vs 52.85%; P < .05), CD8 + T cells (62.94% vs 29.76%; P < .05), and CD3 + T cells (69.72% vs 45.49%; P < .05) in an A-CCRT-P (after treatment with radiotherapy plus chemotherapy plus the probiotic combination) group. Highthroughput sequencing results indicated that CCRT had obviously disturbed the intestinal diversity of patients in an A-CCRT (after treatment with radiotherapy plus chemotherapy plus a placebo) group, whereas the probiotic combination distinctly restored the microbial diversity in the A-CCRT-P group toward that of healthy people and a B-CCRT-P (before the treatment of radiotherapy plus chemotherapy plus the probiotic combination) group. CONCLUSIONS: A probiotic combination significantly enhances the immune response of patients and reduces the severity of OM through modification of gut microbiota.
INTRODUCTION
Nasopharyngeal carcinoma is a common malignant neoplasm in southern China 1 with an overall survival rate exceeding 80%. 2 The mean incidence of oral mucositis (OM) in patients undergoing concurrent radiochemotherapy (CCRT) or altered fractionation radiotherapy is approximately 80% for head and neck cancer. 3 It can compromise quality of life and lead to interruptions in radiotherapy or CCRT at a frequency as high as 19%. 4 Extra supportive care measures add substantially to the total cost of care. 5 There are no effective ways to overcome OM so far. 6 Microbiota have recently been proved to be associated with responses to immunotherapy, whereas the interplay between microbiota, cancer, and the immune system has not been fully defined. [7] [8] [9] [10] As we know, cancer and anticancer treatment greatly weaken the immunity of cancer patients, and this breach of natural protective barriers causes colonization by pathogenic microorganisms. 11 Experimental evidence and some clinical evidence suggest that probiotics, on account of their properties, may have a beneficial effect on the toxicity of radiochemotherapy 7 ; this eventually helps to strengthen homeostasis and thus reduce side effects associated with cancer treatment. 12 There is evidence that Bacteroidales and Bifidobacterium greatly increase the number and activity of immune cells, which then promote the efficacy of anti-cytotoxic T lymphocyte-associated protein 4 and anti-programmed death ligand 1 therapy. 9, 13 For
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MATERIALS AND METHODS

Study Design and Patient Enrollment
The randomized, double-blind, placebo-controlled trial was conducted at Jiangxi Cancer Hospital in China. The trial enrolled patients aged 18 to 70 years who had newly pathologically diagnosed locally advanced nasopharyngeal carcinoma and were undergoing CCRT. All patients were diagnosed as having nasopharyngeal carcinoma without distant metastasis and had a Karnofsky score ≥ 80, and their clinical stages were determined according to the 8th edition of the International Union Against Cancer/American Joint Committee on Cancer TNM classification system. All patients were randomly distributed in a 2:1 ratio to receive probiotics or a placebo (the block size was known only to the statistician), and they received a series of medical evaluations, including a medical history, a physical examination, a magnetic resonance imaging scan of the head and neck, blood testing, abdominal ultrasound, a chest computed tomography scan, and a whole body bone scan, before enrollment. In addition, feces were obtained from 10 healthy people (HP) with microbial diversity analysis. Patients with the following features were excluded: immune diseases, OM or recurrent OM before radiochemotherapy, a high risk for antimicrobial agents, an inability to take medicine orally or absorb medicine in the digestive tract, previous cancer or coexisting tumors, and allergies to probiotics. Patient samples and data were obtained with written informed consent in accordance with the ethics committee requirements at the participating institute and the Declaration of Helsinki. Permission to perform the study was acquired from the institutional review board of the Jiangxi Cancer Hospital.
Randomization and Masking
The random assignment of patients was performed by Nanchang Medical University with a computer-generated random number code. Patients were randomly distributed into 6 blocks in a 2:1 ratio to receive probiotics or a placebo (the block size was known only to the statistician). The drug was distributed and packaged in accordance with random numbers, and the documents stating the parameters, such as the blinding codes for the seeds of the random numbers, the block length, and the random numbers, were sealed in envelopes and stored at Jiangxi Cancer Hospital. Blinding codes were not disclosed during the entire trial period. 14 The critical organs were defined according to the recommendation of Brouwer et al. 15 The oral cavity included the following: the hard palate mucosa and mucosal reflection near the maxilla cranially; the base of the tongue mucosa, hyoid, mylohyoid muscle, and anterior belly of the digastric muscles caudally; the inner surface of the mandible and maxilla anteriorly; the posterior borders of the soft palate, uvula, and base of the tongue posteriorly; and the inner surface of the mandible and maxilla laterally. The probiotic combination (Bifico,SHANGHAI SINE PHARMACEUTICAL CO.LTD, SFDA approval number: S10950032) contained Bifidobacterium longum, Lactobacillus lactis, and Enterococcus faecium. The probiotic or placebo (starch) was supplied from the beginning to the end of treatment for up to 7 weeks (3 capsules 2 times a day). The shape and color of the placebo as well as other properties were devised according to the standards of the Chinese Pharmacopoeia to be identical to those of the probiotic combination. All patients were healthproportioned with conventional oral instructions. Other drugs for treating OM, such as hormones and antibiotics, were not prescribed for grade 1 to 2 OM. Antifungal agents and soda water could be used for patients suffering from oral cavity fungal infections. Patients could drop out of the trial if they were unwilling to take probiotics. However, if these patients had any side effects generated by the probiotic combination, the side effects would have been followed up until they had disappeared. The symptoms, occurrence, and severity of OM were evaluated daily by the researchers according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (version 4.0). 16 An oral mucosal evaluation was performed by at least 2 senior radiation oncologists. Meanwhile, the assessment of the short-term curative effect used
the response rate (the ratio of the number of patients with complete and partial responses to radiotherapy to the total number of patients) in accordance with the Response Evaluation Criteria in Solid Tumors on the basis of magnetic resonance imaging 3 months after the completion of radiochemotherapy. 17 The parameters of routine blood analysis, biochemical analysis, and lymphocyte immunity were measured before and after treatment. General physical examinations, laboratory tests, unplanned delays, vital signs, and so on were completed at the baseline and at the end of the study; body weight was recorded once a week.
Total Bacterial Genomic DNA Extraction and High-Throughput Sequencing
Patients in the HP group (n = 10), B-CCRT (before the treatment of radiotherapy plus chemotherapy plus a placebo) group (n = 10), B-CCRT-P (before the treatment of radiotherapy plus chemotherapy plus the probiotic combination) group (n = 10), A-CCRT (after treatment with radiotherapy plus chemotherapy plus a placebo) group (n = 10), and A-CCRT-P (after treatment with radiotherapy plus chemotherapy plus the probiotic combination) group (n = 10) donated their first feces, which were stored at −70°C. Bacterial DNA was extracted from the samples with a genomic DNA kit (Tiangen) according to the manufacturer's protocols. 18, 19 Total genomic DNA was amplified with a primer pair (338F/806R) that amplified the V3 to V4 region of the 16S ribosomal DNA gene for highthroughput sequencing analysis.
Outcome
The primary efficacy endpoint was severe OM incidence (grade 3 or higher according to the Common Terminology Criteria for Adverse Events, version 4.0). The secondary efficacy endpoints were the short-term curative effect, the immune index, and fecal flora changes.
Statistical Analysis
On the basis of the hypothesis that the average incidence of severe OM (grade 3 or higher) in the placebo group and the probiotic combination group would be 74% 20 and 34%, respectively, 70 patients were needed (2-sided α = .05, 1 -β = 0.9, and 2:1 ratio). We recruited 99 patients, who were randomly assigned, to provide more than adequate power to detect clinically significant differences, and the Fisher exact test was used to evaluate the incidence of different degrees of OM. We analyzed the data for all patients who were randomized and took at least 1 dose of the drug or placebo. The latest value after observation could be applied to accomplish the estimation for missing values of the primary efficacy point. In contrast, the missing values for the major commeasurable analysis of secondary efficacy points were analyzed on the basis of the actual data acquired.
For high-throughput sequencing results, FLASH was used to merge paired-end reads, and those overlapped reads were assigned to each sample on the basis of the unique barcodes (GenBank accession number SRP142561). Then, UPARSE operational taxonomic unit (OTU) and UPARSE-OUT reference algorithms in the UPARSE software package were used for sequence analysis, and the α indexes (within samples) and the β indexes (among samples) were determined with in-house Perl scripts. The Ribosomal Database Project classifier and the unweighted UniFrac distance were used to annotate the taxonomic information and cluster analysis.
All data were reported as means and standard deviations, and the results were analyzed with SPSS 23.0 software (SPSS, Inc, Chicago, Illinois) by means of unpaired F tests. All tests were 2-tailed with the level of significance set at P < .05.
This trial is registered with Clinical Trials.gov (NCT03112837).
RESULTS
Patients' Baseline Characteristics
Between May 2017 and December 2017, 99 patients were randomly assigned (2:1) to either the probiotic combination group (64 patients) or the placebo group (35 patients) . No patient in the placebo group was excluded from the full-analysis set, and 4 patients who received at least 1 dose of the drug were automatically withdrawn from the study (in the probiotic group) because of a failure to undergo follow-up or at their request but not because of grade 3 or higher mucositis. In addition, another 2 patients were excluded from the protocol set because of poor drug compliance.
Sex, age, baseline characteristics, and tumor classification for all patients are summarized in Table 1 . Thirtyfive patients were designated as the CCRT group, and 58 patients were designated as the CCRT-P (CCRT + probiotic combination) group (Fig. 1) . The treatment groups were well balanced, and there was no marked difference between the CCRT group and the CCRT-P group.
By the end of the trial, 1 patient (2.86%) in the placebo group and 2 patients (3.1%) in the probiotic Cancer April 1, 2019 combination group had not completed 2 cycles of chemotherapy in the full-analysis set. In the per-protocol set, 97.14% of the patients (34 of 35) in the placebo group and 100% of the patients (58 of 58) in the probiotic combination group received at least 2 cycles of chemotherapy. All patients in these 2 groups received 100% of the planned radiation treatment dose. In the per-protocol set, the median dose to the oral cavity in the probiotic combination group (3967 cGy) was significantly higher than the dose in the placebo group (3751 cGy; P < .05). The median radiation doses to the left parotid gland in the CCRT group and the CCRT-P group were 3352 ± 79.29 cGy and 3272 ± 63.95 cGy, respectively (P = .7099). The median doses to the right parotid gland in the CCRT group and the CCRT-P group were 3832 ± 503.2 cGy and 3215 ± 142.20 cGy, respectively (P = .8454). The median dose to the left submandibular gland was 6181 ± 133.30 cGy in the Abbreviations: CCRT, concurrent radiochemotherapy; CCRT-P, the treatment of radiotherapy plus chemotherapy plus the probiotic combination; SD, standard deviation. Cancer April 1, 2019
CCRT group and 5625 ± 387.7 in the CCRT-P group (P = .4206). The median dose to the right submandibular gland was 5923 ± 155.6cGy in the CCRT group and 6071 ± 459.40 cGy in the CCRT-P group (P = .8413). Twenty percent of the patients in the CCRT group (7 of 35) had an unplanned delay (normally it was no more than 3 days), whereas 0 patients did in the CCRT-P group (Tables 1 and 2) . No serious adverse events were observed, and adverse events occurred in 33 of the 35 patients (94.3%) in the placebo group and in 53 of the 58 patients (91.4%) in the probiotic combination group. According to our observations, the most frequent side effects (8%) were caused by reduced levels of leukocytes (23.5% vs 23.0%), hemoglobin (23.2% vs 18.4%), erythrocytes (12.3% vs 10.3%), and lymphocytes (30.6% vs 30.8%). In addition, mild or moderate gastrectasia reactions were also associated with the probiotic combination, with an overall incidence of 1.72% (1 of 58 patients; data not shown).
Probiotic Combination Reduced OM by Improving the Immunity of Patients
As shown in Table 2 , the incidences of grade 0, 1, 2, and 3 OM in the placebo group and the probiotic combination group for the full-analysis set were 0% and 10.94%, 0% and 51.56%, 54.29% and 21.88%, and 45.71% and 15.63%, respectively. They were 0% and 12.07%, 0% and 55.17%, 54.29% and 17.24%, and 45.71% and 15.52%, respectively, for the per-protocol set; this was consistent with the full-analysis set. The complete response rates were 31 of 35 (88.57%) and 51 of 58 (87.9%), and the partial response rates were 4 of 35 (11.43%) and 7 of 58 (12.1%; P >. 999). These results indicate that the probiotic combination reduced the incidence of grade 3 OM and had a similar overall response rate (Table 2 and Supporting Fig. 1 (Table 3) . However, the probiotic combination did not reduce the suppression of bone marrow (1.88 vs 2.18), weight loss (6.11% vs 6.11%), or the reduction rates of lymphocytes (69.05% vs 69.89%), leukocytes (-8.65% vs -4.55%), hemoglobin (13.57% vs 13.57%), and albumin (8.803% vs 11.09%) (P > 0.05; Fig. 2) .
Effects of the Probiotic Combination on the Composition and Relative Abundance of Bacterial Communities
In total, 3,026,060 clean tags and 9820 OTUs were obtained with an average of 196.4 OTUs in each group; this number was sufficient for further high-throughput sequencing analysis (Supporting Table 1 ). As shown in Figure 3A , at the phylum level, Firmicutes, Bacteroidetes, Proteobacteria, and Actinobacteria constituted the 4 most common dominant phyla in the HP, B-CCRT, A-CCRT, B-CCRT-P, and A-CCRT-P groups (Firmicutes, 65.20%, 69.59%, 51.62%, 61.18%, and 46.03%, respectively; Bacteroidetes, 28.73%, 18.70%, 26.37%, 23.65%, and 30.45%, respectively; Proteobacteria, 4.57%, 8.90%, 12.18%, 10.51%, and 17.12%, respectively; and Actinobacteria, 1.18%, 2.21%, 9.36%, 3.23%, and 5.03%, respectively), and their numbers accounted for 99.69%, 99.41%, 99.52%, 98.56%, and 98.63%, respectively. Moreover, a Venn figure reflecting the differences between the groups is Abbreviations: CCRT, concurrent radiochemotherapy; CCRT-P, the treatment of radiotherapy plus chemotherapy plus the probiotic combination.
Cancer April 1, 2019 depicted in Figure 3B . A comparison of all the groups indicated that 316 common OTUs were identified in all the groups; 5 and 6 of these OTUs belonged to Bifidobacterium and Lactobacillus, respectively. In addition, a principal coordinate analysis was conducted, and the results indicated that samples from the HP, B-CCRT, and A-CCRT-P groups clustered together, whereas samples from the A-CCRT group scattered far from the samples from these groups. Compared with samples from the A-CCRT group, samples from the A-CCRT-P group were closer to samples from the HP group (Fig. 3) .
DISCUSSION
Our results indicated that the probiotic combination had significantly reduced OM by improving the immunity of the patients. The findings showed that 45.71% of the patients in the CCRT group developed grade 3 OM, whereas only 15.52% did in the CCRT-P group, and this supported the protective effect of the probiotic combination against OM. It should be noted that the tumor response to CCRT was not affected by the probiotic combination because all enrolled patients reached parallel objective response rates. This result is similar to the results of a study indicating that 1 probiotic, Figure 2 . Effects of the probiotic combination on (A) the reduction rate of CD3 + T cells, (B) the reduction rate of CD4 + T cells, (C) the reduction rate of CD8 + T cells, (D) the suppression index of bone marrow, (E) the reduction rate of lymphocytes, (F) the reduction rate of leukocytes, (G) the reduction rate of hemoglobin, (H) weight loss, and (I) the reduction rate of albumin. *P < .05. A-CCRT indicates after treatment with radiotherapy plus chemotherapy plus a placebo; A-CCRT-P, after treatment with radiotherapy plus chemotherapy plus the probiotic combination.
Cancer April 1, 2019 Lactobacillus brevis CD2, had reduced the incidence of radiochemotherapy-induced OM (grades 3 and 4) in patients with head and neck squamous cell carcinoma undergoing chemoradiotherapy. 21 A change in the saliva quality is one of the pathogeneses of radiation damage to the oral mucosa. 22 Damage to the salivary glands arising from radiation therapy limits the combining ability of large salivary glycoproteins (eg, immunoglobulin A) covering the surface of the oral mucosa. Glycoproteins reduce the adherence of microorganisms to the oral mucosa and serve as a protective shield for the superficial cells in the oral cavity. The absence of the glycoproteins' protective capability renders the epithelial cells more susceptible to irritation. [23] [24] [25] B. longum, L. lactis, and E. faecium have the potential to be the backbone of cancer therapy and to be used in cancer care in the future. Evidence has indicated that exposure to probiotics boosts the initiation of memory T and B cells, adaptive immunity, and the immune system and corrects the microbial-based education of immune cells, which may affect the production of immunoglobulin A. 26 The administration of the probiotic combination significantly enhanced T-cell numbers in comparison with those of B-CCRT-P patients treated with equivalent irradiation doses to the oral cavity, left/ right parotid gland, and left/right submandibular gland (Tables 1 and 2 28 Therefore, the significance of enhanced numbers of CD3 + T cells, CD8 + T cells, and CD4 + T cells in the A-CCRT-P group indicated that the probiotics confirmed their roles in modulating human immune responses to pathogens and tumor cells and were important in orchestrating overall immune responses. 7, 29 Moreover, we also calculated the numbers of patients with health-related blood indicators in the A-CCRT and A-CCRT-P groups and found that the probiotic combination had markedly restored the CD3 + T cells, CD4 + T cells, CD8 + T cells, hemoglobin, and lymphocyte ratio to the normal levels (Table 3) .
Commensal bacteria and other microorganisms compose the microbiota in human intestines, and they influence the initiation, progression, and dissemination of cancers. 7 In this study, we monitored the dynamic changes of intestinal microbiota rather than oral microbiota as in other studies using high-throughput sequencing because of the small sample size and instability of oral microbiota. 30, 31 Our results indicated that Firmicutes, Bacteroidetes, Proteobacteria, and Actinobacteria constituted the dominant phyla and accounted for a majority of the total sequencing numbers in the HP, B-CCRT, A-CCRT, B-CCRT-P, and A-CCRT-P groups (Fig. 3) . Previous studies have indicated that Firmicutes makes up the largest portion of the mouse and human gut microbiota, and it has been shown to be related to energy resorption and potentially involved in the development of diabetes and obesity. [32] [33] [34] For Bacteroidetes, its existence in the human intestinal tract has a strong connection with nutritional modulation and adverse effects of chemotherapy Abbreviations: A-CCRT, after treatment with radiotherapy plus chemotherapy plus a placebo; A-CCRT-P, after treatment with radiotherapy plus chemotherapy plus the probiotic combination.
Cancer April 1, 2019 during cancer therapy. 35 When the principal coordinate analysis was conducted, our results suggested that CCRT had obviously disturbed the intestinal diversity of the patients, and the samples from the A-CCRT group scattered far from the samples from the HP and B-CCRT groups, whereas the administration of the probiotic combination markedly restored the microbial diversity in the A-CCRT-P group toward that of the HP and B-CCRT-P groups in comparison with the CCRT group. This indicated that the probiotic combination had greatly enhanced the efficacy and reduced the toxicity of chemotherapeutic agents and radiotherapy by sustaining the bacterial homeostasis of the intestines (Fig. 3) . In addition, the probiotic combination used in the current study was safe and well tolerated, and no drug-related trends were apparent in the incidence of adverse events. Therefore, supplementation with the probiotic combination could effectively reduce the intestinal microbial disturbances caused by radiochemotherapy and directly or indirectly enhance the capacity for food digestion, absorption, energy production, and immunity, and this could eventually reduce OM in patients with nasopharyngeal carcinoma. For the first time, this study indicated that the probiotic combination had significantly enhanced the immunity of patients, reduced OM, and was beneficial for restoring A-CCRT indicates after treatment with radiotherapy plus chemotherapy plus a placebo; A-CCRT-P, after treatment with radiotherapy plus chemotherapy plus the probiotic combination; B-CCRT, before the treatment of radiotherapy plus chemotherapy plus a placebo; B-CCRT-P, before the treatment of radiotherapy plus chemotherapy plus the probiotic combination; HP, healthy people; PC1, principal coordinate 1; PC3, principal coordinate 3; PCoA, principal coordinate analysis. microbial diversity after the end of CCRT. Therefore, this randomized clinical trial shows the benefits of oral probiotics for preventing OM in patients with cancer during radiochemotherapy. Future studies should be performed for the optimization of the dose and regimen with a larger group of patients, and animal experiments should be performed to explore the potential mechanisms that underlie its sound effect.
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